Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Zak

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry Letters|September 18, 2013
Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitorsSharada Labadie, Kathy Barrett, Wade S Blair, et al.
The Journal of Allergy and Clinical Immunology|March 21, 2021
Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trialIrene E Braithwaite, Fang Cai, Jennifer A Tom, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 16, 2014
Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferaseTanja S Zabka, Jatinder Singh, Preeti Dhawan, et al.
Bioorganic & Medicinal Chemistry Letters|August 1, 2013
Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Peter S Dragovich, Kenneth W Bair, Timm Baumeister, et al.
Journal of Medicinal Chemistry|August 20, 2016
Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) InhibitorsMark Zak, Po-Wai Yuen, Xiongcai Liu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 4, 2019
Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic ModalitiesDonglu Zhang, Cornelis E C A Hop, Gabriela Patilea-Vrana, et al.
Bioorganic & Medicinal Chemistry Letters|January 18, 2014
Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Peter S Dragovich, Guiling Zhao, Timm Baumeister, et al.
Bioorganic & Medicinal Chemistry Letters|November 28, 2013
Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitorsXiaozhang Zheng, Timm Baumeister, Alexandre J Buckmelter, et al.
Nature|August 13, 2013
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancersGeorgia Hatzivassiliou, Jacob R Haling, Huifen Chen, et al.
Journal of Medicinal Chemistry|April 27, 2013
Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitorsXiaozhang Zheng, Paul Bauer, Timm Baumeister, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|September 18, 2013
Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitorsSharada Labadie, Kathy Barrett, Wade S Blair, et al.
The Journal of Allergy and Clinical Immunology|March 21, 2021
Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trialIrene E Braithwaite, Fang Cai, Jennifer A Tom, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 16, 2014
Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferaseTanja S Zabka, Jatinder Singh, Preeti Dhawan, et al.
Bioorganic & Medicinal Chemistry Letters|August 1, 2013
Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Peter S Dragovich, Kenneth W Bair, Timm Baumeister, et al.
Journal of Medicinal Chemistry|August 20, 2016
Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) InhibitorsMark Zak, Po-Wai Yuen, Xiongcai Liu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 4, 2019
Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic ModalitiesDonglu Zhang, Cornelis E C A Hop, Gabriela Patilea-Vrana, et al.
Bioorganic & Medicinal Chemistry Letters|January 18, 2014
Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Peter S Dragovich, Guiling Zhao, Timm Baumeister, et al.
Bioorganic & Medicinal Chemistry Letters|November 28, 2013
Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitorsXiaozhang Zheng, Timm Baumeister, Alexandre J Buckmelter, et al.
Nature|August 13, 2013
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancersGeorgia Hatzivassiliou, Jacob R Haling, Huifen Chen, et al.
Journal of Medicinal Chemistry|April 27, 2013
Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitorsXiaozhang Zheng, Paul Bauer, Timm Baumeister, et al.
Pageof 4